RPLP1 and clostridium difficile infection: Both LP1 and LP2 lipoproteins can be used together with other potential immunogens (C. difficile surface proteins, toxin fragments or spores coat proteins) for development of fusion immunogens leading towards a protective vaccine against CDI, with LP2 being a more potent immunogen.